Literature summary for 1.16.3.1 extracted from

Boll, M.C.; Alcaraz-Zubeldia, M.; Montes, S.; Rios, C.
Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases (2008), Neurochem. Res., 33, 1717-1723.

Search for more literature for 1.16.3.1

Application

Application	Comment	Organism
medicine	in fluid from patients with Parkinson's disease, Alzheimer's disease, and Huntington's disease, a significantly decreased ferroxidase activity is found agreeing with findings of iron deposition in these entities, while free copper is found to be increased in cerebrospinal fluid and appears to be a good biomarker of Parkinson's disease. The sum of nitrites and nitrates as end products of nitric oxide are increased in the degenerative diseases Parkinson's disease, Alzheimer's disease, Huntington's disease and lateral amyotrophic sclerosis, and fluorescent lipoperoxidation products in three of them, excepting lateral amyotrophic sclerosis	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	patients with Parkinson's disease, Alzheimer's disease, Huntington's disease and lateral amyotrophic sclerosis	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
cerebrospinal fluid	in fluid from patients with Parkinson's disease, Alzheimer's disease, Huntington's disease, a significantly decreased ferroxidase activity is found agreeing with findings of iron deposition in these entities, while free copper is found to be increased in cerebrospinal fluid and appears to be a good biomarker of Parkinson's disease. The sum of nitrites and nitrates as end products of nitric oxide are increased in the degenerative diseases Parkinson's disease, Alzheimer's disease, Huntington's disease and lateral amyotrophic sclerosis and fluorescent lipoperoxidation products in three of them, excepting lateral amyotrophic sclerosis	Homo sapiens	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)